$8.0M
+$8.0M this year1 filing since 2026 · latest Equity filed
Aptamino is an early-stage biotechnology company working on oral delivery of antibody therapeutics using computational protein design. It was co-founded by CEO Julie Zhang and Isaac Lutz, who previously worked together in the George Church lab at Harvard Medical School; Lutz did his bioengineering PhD in the Baker Lab, applying reinforcement learning and generative AI to protein design. The company is operating in stealth from Cambridge, Massachusetts, with backing that includes The Engine.
What sets it apart
Applies computational and generative protein design — the founders' background in machine-learning-driven protein engineering — to the delivery problem, aiming to make antibodies administrable orally rather than by injection or infusion.
A protein-design-based approach intended to let antibody therapeutics survive oral administration and reach systemic circulation, in place of injection or infusion. The program is pre-launch and no product name or pipeline detail has been disclosed publicly.
